Diabetes Drug Metformin Under Investigation By The FDA

December 20, 2019 4:56 pm Published by

Outside of the United States low levels of the carcinogen N-nitrosodimethylamine (NDMA) were found in the diabetes drug Metformin, this has promoted the U.S. Federal Drug Administration (FDA) to open a formal investigation into the diabetes treatment here in the U.S..

Typically low levels of N-nitrosodimethylamine (NDMA) can be found in certain foods and water here in the United States but these levels have been deemed not harmful by the FDA and are acceptable for human consumption. After the recall of Zantac earlier this year for similar issues, this announcement is largely seen as precautionary by the FDA.

Officials are recommending that those who are using Metformin continue to do so until otherwise instructed. While there may be a risk of this cancer-causing chemical, the greater risk is that people with Type 2 Diabetes (especially severe cases) stop taking this drug all together.

There are four brand names that the drug is labeled under Glucophage, Glucophage XR, Fortamet, and Glumetza. There is currently no alternative to this medication.